Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q24243105)
Watch
English
Dopamine agonist therapy in early Parkinson's disease
scientific article
In more languages
default for all languages
No label defined
No description defined
edit
Statements
instance of
scholarly article
0 references
meta-analysis
0 references
review article
1 reference
stated in
Europe PubMed Central
title
Dopamine agonist therapy in early Parkinson's disease
(English)
0 references
main subject
Parkinson's disease
1 reference
based on heuristic
inferred from title
dopamine
0 references
author
Rebecca Stowe
series ordinal
1
0 references
Natalie Ives
series ordinal
2
0 references
Keith Wheatley
series ordinal
8
0 references
Joaquim Ferreira
object named as
Joaquim Ferreira
series ordinal
5
0 references
Richard Gray
object named as
Richard Gray
series ordinal
9
0 references
Carl E Clarke
series ordinal
3
object named as
Carl E Clarke
0 references
Laila Shah
series ordinal
7
object named as
Laila Shah
0 references
author name string
van Hilten
series ordinal
4
0 references
Robert J Hawker
series ordinal
6
0 references
publication date
23 April 2008
0 references
published in
Cochrane Database of Systematic Reviews
0 references
cites work
Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The effect of deprenyl and levodopa on the progression of Parkinson's disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Factors impacting on quality of life in Parkinson's disease: results from an international survey.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Trial of subtherapeutic pergolide in de novo Parkinson's disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment adherence and risk of death after a myocardial infarction
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment interventions for Parkinson's disease: an evidence based assessment
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: results of a multicentre, randomized, double-blind, placebo-controlled study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Does combined levodopa and bromocriptine therapy in Parkinson's disease prevent late motor complications?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of deprenyl on the progression of disability in early Parkinson's disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Levodopa and the progression of Parkinson's disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dihydroergocryptine in the Treatment of Parkinsonʼs Disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dihydroergocryptine in the treatment of Parkinson's disease: a six months' double-blind clinical trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pramipexole in patients with early Parkinson's disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifying relevant studies for systematic reviews
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Science, medicine, and the future: Parkinson's disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Evaluating drug treatments for Parkinson's disease: how good are the trials?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Medical management of Parkinson's disease.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term double masked trial of early treatment with L-dopa plus bromocriptine versus L-dopa alone in Parkinson's disease. Interim results
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The statistical basis of meta-analysis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F14651858.CD006564.PUB2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1002/14651858.CD006564.PUB2
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
562736
Fatcat ID
release_4os4hzu3h5dv5d3a44s55qgily
1 reference
stated in
Fatcat
reference URL
https://api.fatcat.wiki/v0/release/4os4hzu3h5dv5d3a44s55qgily
retrieved
24 November 2022
based on heuristic
mapped directly with Wikidata item
OpenCitations bibliographic resource ID
562736
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
562736
PubMed publication ID
18425954
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
562736
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit